Oncology

Team RSC: RNA Splicing in Cancer

Emerging data indicate that alterations in RNA splicing play a critical role in the pathogenesis of several molecular subtypes of cancer. Such alterations can lead to constitutive activity of oncogenes, reduced expression of tumor suppressors, or drug resistance. The team is seeking to identify novel approaches to exploit tumor-specific RNA splicing alterations for targeted cancer therapy.

Mentors

  • Dr. Christina Esdar
    Associate Director TIP Oncology at Merck, Darmstadt, Germany (Industry mentor)
  • Prof. Dr. Andreas Kulozik
    Head of the Department of Pediatric Oncology, Hematology, Immunology and Pulmonology at Children’s Hospital, University of Heidelberg, Germany (Academic mentor)
The research of this team is kindly sponsored by Merck.
The research of this team is kindly sponsored by Merck.

Our Team Members

Dr. Jan Mauer

Group Leader

Previous work
  • 2015-2017: Postdoc in RNA biology and epitranscriptomics with Prof. Samie R. Jaffrey at the Department of Pharmacology, Weill Cornell Medicine of Cornell University, New York, USA
  • 2009-2014: Postdoc in mouse models of metabolic and inflammatory diseases with Prof. Jens C. Brüning, at the Institute for Genetics, University of Cologne, Germany and at the Max Planck Institute for Metabolism Research in Cologne, Germany
  • 2004-2009: PhD in Genetics with Prof. Jens C. Brüning at the Institute for Genetics, University of Cologne, Germany